Correction to: Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy (Annals of Hematology, (2025), 104, 10, (5223-5236), 10.1007/s00277-025-06602-9)

Jiang B.Li J.Liu L.Du X.Jiang H.Hu J.Zeng X.Sakatani T.Kosako M.Deng Y.Ivanov V.Bondarenko S.Lee L.W.L.Khuhapinant A.Martynova E.Hasabou N.An J.J.H.Wang J.Mahidol University2026-02-192026-02-192026-03-01Annals of Hematology Vol.105 No.3 (2026)09395555https://repository.li.mahidol.ac.th/handle/123456789/115166In the published paper, the median event-free survival of the gilteritinib arm was incorrectly presented in Fig. 4. The median value ‘21’ should be presented as ‘2.1’. The original article has been corrected.MedicineCorrection to: Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy (Annals of Hematology, (2025), 104, 10, (5223-5236), 10.1007/s00277-025-06602-9)ErratumSCOPUS10.1007/s00277-026-06880-x2-s2.0-10502986849914320584